Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
Unbranded HCP APS
-
Good afternoon,
Hypothetically, might it be acceptable to develop an unbranded APS directed to HCP with an educational focus on an emerging therapeutic technology, given that i) the APS would have no mention of or linkage to any condition or therapeutic area, ii) the technology is not exclusively applied to one therapeutic area, and iii) such technology is already utilized in pharmaceuticals that have been approved in Canada?
Thank you.
-
Hello @colin
This sounds like it might be possible in an APS that is both product and disease agnostic but it is difficult to say with confidence without knowing the emerging technology, it’s approved applications, the discussions within the piece and their implications to current or future therapeutic areas etc. If the specific example cannot be provided in a public forum, an opinion may be a better option.
